Filtered By:
Management: Funding

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 373 results found since Jan 2013.

AMA1-RON2 Complex-based Vaccine Against Malaria
This technology relates to a malaria vaccine composed of a protein complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 (RON2) with an adjuvant. AMA1 is a crucial component of the <em>Plasmodium</em> invasion machinery and is a leading candidate for antimalarial vaccine development. AMA1-based vaccines have shown ability to block red cell invasion in <em>in vitro</em> assays, but protection has so far not translated to <em>in vivo</em> human infections. NIAID investigators have demonstrated that interaction between AMA1 and RON2 (or peptide thereof) is essential for mala...
Source: NIH OTT Licensing Opportunities - June 18, 2014 Category: Research Authors: admin Source Type: research

Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature
To improve the transparency and reporting of clinical trials, the US Congress passed the Food and Drug Administration Amendments Act (FDAAA) of 2007, which requires investigators to upload their results of investigational phase 2 to 4 drug, biologic, and device trials within 1 year of the trial's completion.1 Noncompliance can result in the withholding of National Institutes of Health grant funding and civil monetary penalties of up to $10,000.2 However, a recent report found that only 22% of qualifying studies had uploaded results within the required timeframe.
Source: Journal of Allergy and Clinical Immunology - October 28, 2014 Category: Allergy & Immunology Authors: Chris Stockmann, Joseph S. Ross, Catherine M.T. Sherwin, Christopher A. Reilly, Brittany McDowell, Bernhard Fassl, Flory Nkoy, Christopher G. Maloney, Michael G. Spigarelli Tags: Letter to the Editor Source Type: research

UW-Madison awarded $70M NIH grant for asthma research
The University of Wisconsin School of Medicine and Public Health in Madison has been awarded a grant of $70 million for an ongoing research project into inner-city children with asthma. The grantfrom the National Institute of Allergy and Infectious Diseases — the largest grant ever for the school — increases the total amount of NIH funding for the project, the Inner-City Asthma Consortium, to more than $190 million since 2002. The Inner-City Asthma Consortium is a nationwide clinical research…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 10, 2014 Category: Pharmaceuticals Authors: David Schuyler Source Type: news

Now That The Election Is Over, Congress Seems To Have Calmed Down About Ebola
WASHINGTON -- The near-hysterical mood of congressional hearings on Ebola before the elections was replaced Wednesday by measured, reassuring debate in a Senate Appropriations Committee hearing. The committee held a hearing to discuss the White House's request for $6.2 billion to combat the epidemic. The Obama administration is asking for the money to ramp up efforts to control Ebola in Africa, prepare hospitals in the United States and develop treatments for the deadly virus. Before the midterm elections, lawmakers in the House had hectored the nation's top medical experts in congressional hearings, often cutting them o...
Source: Healthy Living - The Huffington Post - November 12, 2014 Category: Consumer Health News Source Type: news

LSU Health New Orleans research targets deadly intra-abdominal infections
(Louisiana State University Health Sciences Center) Mairi Noverr, Ph.D., associate professor of prosthodontics at LSU Health New Orleans School of Dentistry's Center of Excellence in Oral Biology, has been awarded a $1.8 million grant by the National Institute of Allergy and Infectious Diseases. The funding will support research to reduce the death rate from intra-abdominal infections caused by both fungal and bacterial pathogens. These types of polymicrobial infections are increasingly common among hospitalized patients, have a high death rate, and there has been little research in this area.
Source: EurekAlert! - Medicine and Health - November 13, 2014 Category: Global & Universal Source Type: news

UCLA researcher pioneers gene therapy cure for ‘Bubble Baby’ disease
UCLA stem cell researchers have pioneered a stem cell gene therapy cure for children born with a life-threatening condition called adenosine deaminase–deficient severe combined immunodeficiency, or ADA-deficient SCID. Often called Bubble Baby disease, the condition can be fatal within the first year of life if left untreated. The groundbreaking treatment was developed by Dr. Donald Kohn, a renowned stem cell researcher and member of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research . Kohn’s breakthrough was developed over three decades of research aimed at creating a gene therapy that...
Source: UCLA Newsroom: Health Sciences - November 20, 2014 Category: Universities & Medical Training Source Type: news

UCLA study: To stop spread of HIV, African governments should target hot zones
David Gerberry Efficiency of reducing transmission of HIV in South African provinces, from red (best) to orange (moderate) to green (worst). Blue and pink bars show prevalence of HIV for men and women, respectively. While Ebola has attracted much of the world’s attention recently, a severe HIV epidemic rages on around the world and in sub-Saharan Africa in particular. Globally, more than 34 million people are infected with HIV; in sub-Saharan Africa alone, 3 million new infections occur annually. In an attempt to stop the spread of HIV, governments in the region are considering providing antiretroviral drugs to people w...
Source: UCLA Newsroom: Health Sciences - December 2, 2014 Category: Universities & Medical Training Source Type: news

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
This study represents an important step in vaccine development to combat this rapidly emerging pathogen. Further studies should be done in a larger number of participants and in more diverse populations. Funding Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, and National Institutes of Health.
Source: The Lancet - December 5, 2014 Category: Journals (General) Source Type: research

UCLA researchers unlock protein key to harnessing regenerative power of blood stem cells
In this study, the authors showed that a cell surface protein called protein tyrosine phosphatase-sigma (PTP-sigma) regulates the critical process called engraftment, which is how HSCs start to grow and make healthy blood cells after transplantation. Mamle Quarmyne, a graduate student Chute’s lab and first author of the study, demonstrated that PTP-sigma is produced (expressed) on a high percentage of mouse and human HSCs. She showed further that genetic deletion of PTP-sigma in mice markedly increased the ability of HSCs to engraft in transplanted mice.  In a complementary study, Quarmyne demonstrated that selection o...
Source: UCLA Newsroom: Health Sciences - December 8, 2014 Category: Universities & Medical Training Source Type: news

Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial
Publication date: Available online 11 December 2014 Source:The Lancet HIV Author(s): Robert Gross , Lu Zheng , Alberto La Rosa , Xin Sun , Susan L Rosenkranz , Sandra Wagner Cardoso , Francis Ssali , Rob Camp , Catherine Godfrey , Susan E Cohn , Gregory K Robbins , Anthony Chisada , Carole L Wallis , Nancy R Reynolds , Darlene Lu , Steven A Safren , Lara Hosey , Patrice Severe , Ann C Collier Background Adherence is key to the success of antiretroviral therapy. Enhanced partner support might benefit patients with previous treatment failure. We aimed to assess whether an enhanced partner-based support intervention with mo...
Source: The Lancet HIV - December 11, 2014 Category: Infectious Diseases Source Type: research

Designing Drug Trials: Considerations for Pregnant Women
Clinical pharmacology studies that describe the pharmacokinetics and pharmacodynamics of drugs in pregnant women are critical for informing on the safe and effective use of drugs during pregnancy. That being said, multiple factors have hindered the ability to study drugs in pregnant patients. These include concerns for maternal and fetal safety, ethical considerations, the difficulty in designing appropriate trials to assess the study objectives, and funding limitations. This document summarizes the recommendations of a panel of experts convened by the Division of Microbiology and Infectious Diseases at the National Instit...
Source: Clinical Infectious Diseases - November 25, 2014 Category: Infectious Diseases Authors: Sheffield, J. S., Siegel, D., Mirochnick, M., Heine, R. P., Nguyen, C., Bergman, K. L., Savic, R. M., Long, J., Dooley, K. E., Nesin, M. Tags: INCLUDING PREGNANT WOMEN IN CLINICAL TRIALS OF ANTIMICROBIALS AND VACCINES Source Type: research

Erratum
In the article, “Growth Comparison in Children with and without Food Allergies in 2 Different Demographic Populations,” by Mehta et al (J Pediatr 2014;165:284-8), incomplete funding information was published in error. The correct funding information is: J.W. is funded by the National Institutes of Health/National Institutes of Allergy and Infectious Diseases (K23 AI083883). H.M. is funded by The Louis and Rachel Rudin Foundation, Inc. The authors declare no conflicts of interest.
Source: The Journal of Pediatrics - December 18, 2014 Category: Pediatrics Tags: Erratum Source Type: research

A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study
Publication date: January 2015 Source:The Lancet Haematology, Volume 2, Issue 1 Author(s): John E Levine , Thomas M Braun , Andrew C Harris , Ernst Holler , Austin Taylor , Holly Miller , John Magenau , Daniel J Weisdorf , Vincent T Ho , Javier Bolaños-Meade , Amin M Alousi , James L M Ferrara Background Graft-versus-host disease (GVHD) is the major cause of non-relapse mortality after allogeneic haemopoietic stem-cell transplantation (SCT). The severity of symptoms at the onset of GVHD does not accurately define risk, and thus most patients are treated alike with high dose systemic corticosteroids. We aimed to define c...
Source: The Lancet Haematology - January 8, 2015 Category: Hematology Source Type: research

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
This study is registered with ClinicalTrials.gov, number NCT01805882. Findings Between Jan 11, 2013, and Dec 17, 2013, we enrolled 60 patients, and sequentially assigned them into three groups of 20. We noted an SVR12 in all 20 patients (100%, 95% CI 83–100) allocated to sofosbuvir and ledipasvir for 12 weeks; in 19 (95%, 75–100) of the 20 patients allocated to sofosbuvir, ledipasvir, and GS-9669 for 6 weeks (one patient relapsed 2 weeks after completion of treatment); and in 19 (95%, 75–100%) of the 20 patients allocated to sofosbuvir, ledipasvir, and GS-9451 for 6 weeks (one patient was lost to follow-up after rea...
Source: The Lancet - January 13, 2015 Category: Journals (General) Source Type: research

NIH awards 7-year grant to Weill Cornell to tackle global tuberculosis epidemic
(Weill Cornell Medical College) In an effort to stop tuberculosis from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration among six institutions in close alliance with voluntary pharmaceutical partners. The total funding, provided by the National Institute of Allergy and Infectious Diseases, could be up to $45.7 million over seven years.
Source: EurekAlert! - Medicine and Health - February 18, 2015 Category: Global & Universal Source Type: news